Efanesoctocog Alfa Treatment 'Victory' for Hemophilia A Patients

A once-weekly prophylactic treatment of this investigational agent led to normal or near-normal factor VIII activity levels in most patients with severe hemophilia A.

Related Keywords

Louisiana ,United States ,New Orleans ,Michigan ,Cindy Leissinger ,Angela Weyand ,Louisiana Center ,University Of California San Diego ,Disorders At Tulane University School Of Medicine ,Drug Administration ,Michigan Medicine ,New England Journal ,California San ,Medscape Medical ,Clotting Disorders ,Tulane University School ,Hemophilia ,Factor Viii ,Prophylaxis ,Hemophilia A ,Pain Management ,Back Pain ,Spain ,Arthralgia ,Ainful Joint ,Joint Pain ,Hemorrhage ,Bleeding ,Quality Of Life ,Pol ,Ealth Related Quality Of Life ,Rqol ,Genetic Disorder ,Anaphylaxis ,Blood ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Genetics ,Headache ,Intraven ,